

4. (Canceled)

5. (Previously Presented) The method of Claim 4 comprising administering to a human or an animal an amount of Bicalutamide sufficient to reduce atherosclerosis.

6. (Original) The method of Claim 5 wherein the effective amount of Bicalutamide is 50 mg as an oral tablet taken daily.

7. (Previously Presented) A method of Claim 5 wherein bicalutamide is administered as a tablet, or as part of a liquid solution or dispersion, or patch, or subcutaneous pellet, or intramuscular injection.

8. (Previously Presented) The method of Claim 4 comprising administering to a human or an animal an amount of Flutamide sufficient to reduce atherosclerosis.

9. (Original) The method of Claim 8 wherein the effective amount of Flutamide is 250 mg orally three times a day.

10. (Previously Presented) A method of Claim 5 wherein flutamide is administered as a tablet, or as part of a liquid solution or dispersion, or patch, or subcutaneous pellet, or intramuscular injection.

11. (Previously Presented) The method of Claim 4 comprising administering to a human or an animal an amount of Nilutamide sufficient to reduce atherosclerosis.

12. (Original) The method of Claim 11 wherein the effective amount of Nilutamide is 50 mg orally three times a day.

13. (Previously Presented) A method of Claim 11 wherein nilutamide is administered as a tablet, or as a part of a liquid solution or dispersion, or patch, or subcutaneous pellet, or intramuscular injection.

Claims 14-15 (Canceled)

16. (Previously Presented) A method of decreasing atherosclerosis comprising administering to a human or an animal in need thereof an amount of a substance selected from the group consisting of leuprolide acetate, goserelin acetate, flutamide, bicalutamide, and nilutamide, which is an inhibitor of the release of LHRH or GnRH resulting in decreased levels of LH.

Claims 17-18 (Canceled)

19. (Previously Presented) The method of Claim 15 comprising administering to a human or an animal an amount of Bicalutamide sufficient to reduce atherosclerosis.

20. (Previously Presented) The method of Claim 19 wherein the effective amount of Bicalutamide is 50 mg as an oral tablet taken daily.

21. (Canceled)

22. (Previously Presented) The method of Claim 15 comprising administering to a human or an animal an amount of Flutamide sufficient to reduce atherosclerosis.

23. (Previously Presented) The method of Claim 15 wherein the effective amount of Flutamide is 250 mg orally three times a day.

24. (Canceled)

October 7, 2004 Reply to Office Action of September 8, 2004

25. (Previously Presented) The method of Claim 15 comprising administering to a human or an animal an amount of Nilutamide sufficient to reduce atherosclerosis.

26. (Canceled)

27. (Previously Presented) The method of Claim 15 wherein nilutamide is administered as a tablet, or as part of a liquid solution or dispersion, or patch, or subcutaneous pellet, or intramuscular injection, or any other method with the intent of accomplishing systemic absorption of the drug sufficient to reduce atherosclerosis.

28. (Previously Presented) The method of Claim 15 wherein nilutamide is administered as a tablet, or as part of a liquid solution or dispersion, or patch, or subcutaneous pellet, or intramuscular injection, or any other method with the intent of accomplishing systemic absorption of the drug sufficient to reduce atherosclerosis.

29. (Canceled)


Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN,
COHEN & POKOTILOW, LTD.

October 7, 2004

Please charge or credit our
Account No. 03-0075 as necessary
to effect entry and/or ensure
consideration of this submission.

By


Kevin A. Keeling
Registration No. 51,867
Customer No. 03000
(215) 567-2010
Attorneys for Applicants